Adjuvant treatment of melanoma

about

Effectiveness of electrochemotherapy after IFN-α adjuvant therapy of melanoma patients Dendritic cell therapy in melanoma.Gold glyconanoparticles coupled to listeriolysin O 91-99 peptide serve as adjuvant therapy against melanoma.

P2860

Q36779843-6466C367-B3CC-4051-9134-C375A933968A Q43923587-901B1B06-2190-4C34-B89B-F17F01EFDD6B Q53159624-21A98A26-C5E6-459D-B19B-D69E9BBB696B

P2860

Adjuvant treatment of melanoma

Item

http://www.wikidata.org/entity/Q36656595

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Adjuvant treatment of melanoma

@ast

Adjuvant treatment of melanoma

@en

type

Item

label

Adjuvant treatment of melanoma

@ast

Adjuvant treatment of melanoma

@en

prefLabel

Adjuvant treatment of melanoma

@ast

Adjuvant treatment of melanoma

@en

P1476

Adjuvant treatment of melanoma

@en

P2093

J A Moreno Nogueira

http://www.w3.org/2001/XMLSchema#string

M Valero Arbizu

http://www.w3.org/2001/XMLSchema#string

R Pérez Temprano

http://www.w3.org/2001/XMLSchema#string

P2860

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Improved survival with MEK inhibition in BRAF-mutated melanoma

Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data.

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.

Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions.

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Resistance to BRAF inhibition in melanomas.

P304

545631

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2013/545631

http://www.w3.org/2001/XMLSchema#string

P478

2013

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235897264

http://www.w3.org/2001/XMLSchema#string

P698

23476798

http://www.w3.org/2001/XMLSchema#string

P932

3588212

http://www.w3.org/2001/XMLSchema#string

Adjuvant treatment of melanoma

about

P2860

P2860

Adjuvant treatment of melanoma

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932